You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美股盤前 | 猴痘概念股繼續上漲

在歐美出現多例猴痘感染病例後,爲天花開發治療藥物和疫苗的生物製藥美股今日盤前繼續上漲,如Emergent BioSolution(EBS.US)、Tonix Pharmaceuticals(TNXP.US)、SIGA Technologies(SIGA.US)等,其中SIGA漲幅最高,達26%。

近期歐美澳多國出現猴痘確診病例,累計確診已過百例。此次疫情爲罕見的非洲以外猴痘疫情,WHO警告或已出現社區傳播。

據悉,猴痘是一種病毒性人畜共患病,其病原體猴痘病毒是一種DNA(脫氧核糖核酸)病毒,屬於痘病毒科正痘病毒屬,與在人類歷史上曾肆虐數千年的天花病毒是“近親”。截至目前,我國還沒有出現過猴痘病例。

猴痘是一種罕見的病毒性疾病,流行於尼日利亞、剛果民主共和國和中非共和國。儘管這種病毒不容易在人與人之間傳播,但其死亡率在1%到15%之間,並且,天花疫苗在預防猴痘方面可提供85%的有效性。

到目前爲止,美國、英國、西班牙均已發出天花疫苗訂單。其中英國和比利時在週末先後宣佈了患者需要21天隔離的政策。

在上週,製藥商SIGA Technologies(SIGA.US)和Chimerix(CMRX.US)漲幅分別達到了68%和41%,而疫苗製造商Emergent Biosolutions(EBS.US)和Bavarian Nordic(BVNRY.US)漲幅則分別達到了23%和79%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account